MRPI — Mera Pharmaceuticals Share Price
Last trade - 00:00- $0.00m
- $0.05m
- $0.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -66.44% | ||
Financial Summary
| Year End 31st Oct | Unit | 2007 | 2008 | 2009 | 2010 | 2011 | 2012E | 2013E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.47 | 0.61 | 0.6 | 0.29 | 0.3 | n/a | n/a | -4.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mera Pharmaceuticals, Inc. is a marine biotechnology company. The Company focuses on photobioreactor technology and owns intellectual property dedicated to the culture of microalgae for biofuel or nutriceutical production. The Company manufactures natural astaxanthin from Haematococcus pluvialis microalgae. Through its research and development, the Company has formulated AstaFactor, an astaxanthin supplement with antioxidant and anti-inflammatory activity, which is available in three formulations, such as rejuvenating formula, sports formula and salmon essentials, such as natural astaxanthin combined with a blend of fish and salmon oil. The Company also produces sea salt products, such as gourmet salt and nigari. The gourmet salt includes Hawaiian Furikake, Hawaiian Furikake refillable grinder, Kona Sea Salt, Kona Sea Salt flake salt case, Kona Sea Salt grinder and Kona Sea Salt grinder case. The Company offers nigari in sizes ranging from one gallon to 250 gallons.
Directors
- Last Annual
- October 31st, 2011
- Last Interim
- October 31st, 2011
- Incorporated
- June 13th, 2002
- Public Since
- June 13th, 2002
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 557,299,676
- Address
- 73-4460 Queen Kaahumanu Hwy Ste 110, KAILUA-KONA, 96740
- Web
- http://www.merapharma.com/
- Phone
- +1 9546482013
- Auditors
- Ligget, Vogt & Webb
Similar to MRPI
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:14 UTC, shares in Mera Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Mera Pharmaceuticals last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Mera Pharmaceuticals share price has underperformed the S&P500 Index by -99.12% over the past year.
There is no consensus recommendation for this security.
Mera Pharmaceuticals does not currently pay a dividend.
Mera Pharmaceuticals does not currently pay a dividend.
Mera Pharmaceuticals does not currently pay a dividend.
To buy shares in Mera Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Mera Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Mera Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MRPI
Based on an overall assessment of its quality, value and momentum Mera Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mera Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -99.14%.
As of the last closing price of $0.00, shares in Mera Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mera Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mera Pharmaceuticals' management team is headed by:
- Benny Doro - PRE
- Charles Spaniak - CFO
- Rafi Markarians - TRS
- Joyce Markley - SEC